N4 Pharma Plc (AIM: N4P), provide details of its work plan following the encouraging data from its oncology research as announced on 13 December 2021. The company sounded very positive with the update released this week.
Share talk spoke with Nigel Theobald, covering the latest announcement and asking him about the market response to news being released by the company, current share price and how often do they have to update the markets?
Have you fully funded all current work streams in Q1/2 in 2022, yes we have more than sufficient funds to carry out the work planned, just a few of the topics raised in the podcast.
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
Listen On
Also Listen
-
Altona Rare Earths PLC (LON:REE) Dr Cedric Simonet spoke with Share Talk
Share Talk interviews Cédric Simonet, CEO of Altona Rare Earths (LON: REE), to d -
Zak Mir talking to Eddie Wyvill, head of Corporate Development – Amaroq Minerals Ltd.
Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine dev -
Zak Mir talking with Nick Tulloch, Chief Executive Officer of Mendell Helium
Zak Mir interviewed Mendell Helium CEO Nick Tulloch regarding M3Helium's new far -
ECR Minerals (AIM:ECR) Chairman Nick Tulloch, MD Mike Whitlow, Technical Consultant Mike Parker and Director Andrew Scott
ECR Minerals, a gold exploration company with assets in Australia, is making sig